525-P: Use of a Remote Thermovisual Monitoring System in High-Risk Patients—A Pilot Study

CAROLINE ABBOTT,KERRYN FRANKLYN,DAVID STUART,ELLEN KIRWAN,SINEAD FLYNN,CAROLINE D. MCINTOSH,ANDREW J. BOULTON
DOI: https://doi.org/10.2337/db24-525-p
IF: 7.7
2024-06-14
Diabetes
Abstract:Introduction: Diabetic foot ulcer (DFU) recurrence rates are high, at 40% in 12 months. We investigated patient adherence to, and effects of, a remote thermovisual monitoring system (Bluedrop Medical) in high-risk diabetic patients. We hypothesized that at-home thermovisual monitoring is easy, used consistently by patients, and may assist podiatry care Methods: In this single arm, open-label, 12-week pilot study in 2 countries, 27 patients with a DFU history were recruited to remote monitoring alongside routine podiatry care. Users were asked to stand on the investigational device (in the form of a home weight scale) for 30s per day at home. Plantar thermal and visual data were captured and transmitted to a cloud-based server for daily review. Scans with abnormalities were reported to patients’ healthcare provider (HCP) who determined best course of intervention. Primary endpoint was mean patient adherence across the study. Likert scales assessed a) HCP reported utility of data to perform remote assessment, b) patient reported device usability Results: Sixteen patients completed 12 study weeks, 11 were withdrawn early (new DFU (7), technical issues) after 59.2 ± 22.3 days. 1,547 daily scans were taken during 1,940 active study days. Mean patient adherence to daily device use was 80% (±19) and 91% had high adherence (≥3 scans/wk). From 73 reported scans: in 62% of cases HCPs did remote interventions (25%) or continued to monitor (37%); in 39% of cases HCPs scheduled in-person care. HCPs strongly agreed/agreed that they could use these data to remotely assess patients’ foot health (96% reports) and help identify issues earlier than standard care (82% reports). HCPs found temperature data useful in 12% of reports vs. 90% for visual data. All patients agreed they were satisfied with the device and found it easy to use Conclusions: Remote monitoring of vulnerable patients was achieved with good adherence, clinical utility and patient satisfaction. Future studies are warranted to assess the impact on DFU prevention Disclosure C. Abbott: Research Support; Bluedrop Medical. K. Franklyn: Research Support; Bluedrop Medical. D. Stuart: Research Support; Bluedrop Medical. E. Kirwan: Research Support; Bluedrop Medical. S. Flynn: Research Support; Bluedrop Medical. C.D. McIntosh: None. A.J. Boulton: None.
endocrinology & metabolism
What problem does this paper attempt to address?